The PBM is pivoting to a cost-based reimbursement model, which it says will reduce variation in how pharmacies are paid.

Initially, Amvuttra’s annual list price will be nearly double the yearly cost of rival medicines from Pfizer and BridgeBio.

A panel of CDC advisers, who had originally been set to meet in February, will discuss the current measles outbreak as well ...

Esteve Química, the CDMO division of leading specialty pharmaceutical company ESTEVE, has been named the Champion of the 2025 CDMO Leadership Award in the Small Molecule API – Global Category. This ...

The pharma is spending $2.5 billion on an R&D center in Beijing. Elsewhere, Adaptimmune warned it could run out of cash and Pfizer sold its remaining stake in Haleon.

Following big announcements from Lilly and Merck, J&J is pledging $55 billion over the next four years to open new plants.

Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...

To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...

Precis Engineering + Architecture, an award-winning design firm with locations in Ambler, PA, and Cary, NC, has hired Kevin J ...

In a groundbreaking achievement, Curetopia, the first Biotech Decentralized Autonomous Organization (DAO) built natively on ...

The deal with startup Dren Bio hands Sanofi a so-called myeloid cell engager that would compete with an array of programs ...

The PBM plans to stop requiring coverage authorization for about 80 drugs, including Vertex’s cystic fibrosis medicines and ...